European Partnership for Personalised Medicine JTC2027 INFORMATION DAY
Date: Dec 3
EP PerMed is organising a Call Information Day on 3 December 2026 from 15:00 to 17:00 CET for the EP PerMed JTC2027 ‘Cell and Gene Therapy for Personalised Medicine (CGT4PM2027)’
Info
- Type: Seminars/Workshops
- Organization: EP PerMed
- Date: Dec 3
- Time: 3:00 pm
- Place: Online
Image: © Igor / Marina – stock.adobe.com | adapted
With this Joint Transnational Call (JTC), EP PerMed will fund research projects in human health on Cell and Gene Therapy (CGT) for personalised medicine (PM) approaches. Proposals must focus on the development and validation of an innovative and novel CGT for PM.
At least one of the following approaches must be employed:
- Somatic cell therapeutics;
- Gene therapeutics;
- Combined cell- and gene therapeutics;
- Novel biological products such as mRNA, other nucleic acid-based methods, and extracellular vesicles as vehicle for gene-based therapeutic procedure.
Research projects in all disease areas are encouraged.
EP PerMed overall aims to:
- Encourage and enable interdisciplinary collaborations, i.e. multi-actor research, by engaging a range of relevant disciplines such as pre-clinical and clinical research, bioinformatics/health informatics/data research, ELSA research, implementation research or health economics research connected to the proposed research topic, including end-user perspective analysis to facilitate the implementation of PM;
- Encourage cross-sectorial collaborations, by including the private sector (e.g. SMEs, small and medium-sized enterprises, industry), as well as regulatory/HTA (health technology assessment) agencies and patient organisations.
The European Partnership for Personalised Medicine, EP PerMed (supported by the European Union under Horizon Europe, Grant Agreement N° 101137129), is a platform for joint programming of national and European regional research and innovation supporting activities putting into action “The Strategic Research & Innovation Agenda (SRIA) for Personalised Medicine (2023)”, SRIA for PM (2023), through dedicated research, development and innovation funding.